Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Changes in Stockholders??? Deficit

v3.24.1
Consolidated Statements of Changes in Stockholders’ Deficit - USD ($)
Series A and B
Convertible Redeemable Preferred Stock
Series C
Preferred Stock
Series C
Special Voting
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Total
Balance at Dec. 31, 2021   $ 2,366,038 $ 8 $ 146,030,350 $ 61,523 $ (88,508,236) $ 59,949,683
Balance (in Shares) at Dec. 31, 2021   309,286 77,505        
Conversion of exchangeable shares to common stock   $ (180,647) 180,647
Conversion of exchangeable shares to common stock (in Shares)       (23,614) 59        
Settlement of convertible notes   $ 1 3,925,499 3,925,500
Settlement of convertible notes (in Shares)         10,371        
Shares withheld for withholding taxes   (9,926) (9,926)
Shares withheld for withholding taxes (in Shares)         (83)        
Shares issued (returned) in connection with 365 Cannabis acquisition     (940,000) (940,000)
Shares issued (returned) in connection with 365 Cannabis acquisition (in Shares)         (699)        
Common shares and warrants issued in connection with unit offering, net of issue costs   $ 11 9,178,950 9,178,961
Common shares and warrants issued in connection with unit offering, net of issue costs (in Shares)         108,696        
Stock-based compensation   843,693 843,693
Stock-based compensation (in Shares)                
Shares issued in connection with the ATM offering program   $ 3 1,854,562 1,854,565
Shares issued in connection with the ATM offering program (in Shares)         32,148        
Issuance of Series A and B convertible redeemable preferred stock, net of issue costs $ 4,294,500  
Issuance of Series A and B convertible redeemable preferred stock, net of issue costs (in Shares) 500,000                
Deemed dividends related to convertible redeemable preferred stock $ 955,500   (955,500) (955,500)
Redemption of convertible redeemable preferred stock $ (5,250,000)  
Redemption of convertible redeemable preferred stock (in Shares) (500,000)                
Settlement of liabilities with shares   49,529 49,529
Settlement of liabilities with shares (in Shares)         110        
Restricted stock vesting       50,000 50,000
Restricted stock vesting (in Shares)       1,014        
Fractional share adjustment from stock split        
Fractional share adjustment from stock split (in Shares)         1,019        
Foreign currency translation adjustments           40,577   40,577
Unrealized losses on convertible notes           245,000   245,000
Net loss   (79,057,610) (79,057,610)
Balance at Dec. 31, 2022   $ 2,185,391 $ 23 160,207,804 347,100 (167,565,846) (4,825,528)
Balance (in Shares) at Dec. 31, 2022   285,672 230,140        
Conversion of exchangeable shares to common stock   $ (285,253)   285,253
Conversion of exchangeable shares to common stock (in Shares)       (37,188) 93        
Common shares issued in a private placement offering   $ 5 499,995 500,000
Common shares issued in a private placement offering (in Shares)         50,000        
Settlement of convertible notes for Series C preferred stock $ 3,422,000   3,422,000
Settlement of convertible notes for Series C preferred stock (in Shares)   3,422              
Settlement of convertible notes   $ 24 3,187,077 3,187,101
Settlement of convertible notes (in Shares)     3,422   237,213        
Stock-based compensation   403,501 403,501
Stock-based compensation (in Shares)                
Restricted stock vesting  
Restricted stock vesting (in Shares)         159        
Foreign currency translation adjustments   (72,100) (72,100)
Unrealized losses on convertible notes   (48,000) (48,000)
Net loss   (11,578,169) (11,578,169)
Balance at Dec. 31, 2023 $ 3,422,000   $ 1,900,138 $ 52 $ 164,583,630 $ 227,000 $ (179,144,015) $ (9,011,195)
Balance (in Shares) at Dec. 31, 2023 3,422   248,484 517,605